JP2019518063A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019518063A5 JP2019518063A5 JP2018566377A JP2018566377A JP2019518063A5 JP 2019518063 A5 JP2019518063 A5 JP 2019518063A5 JP 2018566377 A JP2018566377 A JP 2018566377A JP 2018566377 A JP2018566377 A JP 2018566377A JP 2019518063 A5 JP2019518063 A5 JP 2019518063A5
- Authority
- JP
- Japan
- Prior art keywords
- aryl
- hetaryl
- heterocyclyl
- cycloalkyl
- alkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 0 *[*+]1N=C(*)c(cc2CN3*)c1cc2NC3=O Chemical compound *[*+]1N=C(*)c(cc2CN3*)c1cc2NC3=O 0.000 description 4
- FTYFEXZBNYBQEY-UHFFFAOYSA-N CCNC(Nc(cc1)nc2c1ncc(-c1c[n](CC(C)C)nc1)n2)=O Chemical compound CCNC(Nc(cc1)nc2c1ncc(-c1c[n](CC(C)C)nc1)n2)=O FTYFEXZBNYBQEY-UHFFFAOYSA-N 0.000 description 1
- WUTVMXLIGHTZJC-UHFFFAOYSA-N Cc1c(-c2c[nH]c(C(NC(CO)c3cccc(Cl)c3)=O)c2)nc(Nc(c(Cl)c2)ccc2F)nc1 Chemical compound Cc1c(-c2c[nH]c(C(NC(CO)c3cccc(Cl)c3)=O)c2)nc(Nc(c(Cl)c2)ccc2F)nc1 WUTVMXLIGHTZJC-UHFFFAOYSA-N 0.000 description 1
- AIMJWAQVOUDRCO-ZSOIEALJSA-N NCCCCC(C(/C(/S1)=C/c(cc2)cc3c2OCO3)=O)C1=O Chemical compound NCCCCC(C(/C(/S1)=C/c(cc2)cc3c2OCO3)=O)C1=O AIMJWAQVOUDRCO-ZSOIEALJSA-N 0.000 description 1
- XVECMUKVOMUNLE-UHFFFAOYSA-N Nc1n[nH]c2c1cc(-c1c(cccc3)[n]3nc1-c1ccccc1)nn2 Chemical compound Nc1n[nH]c2c1cc(-c1c(cccc3)[n]3nc1-c1ccccc1)nn2 XVECMUKVOMUNLE-UHFFFAOYSA-N 0.000 description 1
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662352533P | 2016-06-20 | 2016-06-20 | |
| US62/352,533 | 2016-06-20 | ||
| US201662428379P | 2016-11-30 | 2016-11-30 | |
| US62/428,379 | 2016-11-30 | ||
| US201762502996P | 2017-05-08 | 2017-05-08 | |
| US62/502,996 | 2017-05-08 | ||
| PCT/US2017/038084 WO2017222958A1 (en) | 2016-06-20 | 2017-06-19 | Treatment of squamous cell carcinomas with inhibitors of erk |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2019518063A JP2019518063A (ja) | 2019-06-27 |
| JP2019518063A5 true JP2019518063A5 (enExample) | 2020-07-16 |
Family
ID=60783255
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018566377A Pending JP2019518063A (ja) | 2016-06-20 | 2017-06-19 | Ｅｒｋ阻害剤を用いた扁平上皮細胞癌の処置 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20190192517A1 (enExample) |
| EP (1) | EP3471717A4 (enExample) |
| JP (1) | JP2019518063A (enExample) |
| CN (1) | CN109661228A (enExample) |
| TW (1) | TW201805000A (enExample) |
| WO (1) | WO2017222958A1 (enExample) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL3307727T3 (pl) | 2015-06-15 | 2024-07-08 | Asana Biosciences, Llc | Heterocykliczne inhibitory erk1 i erk2 oraz ich zastosowanie w leczeniu nowotworów |
| MX2019006523A (es) | 2016-12-05 | 2019-10-15 | G1 Therapeutics Inc | Conservacion de respuesta inmunitaria durante regimenes de quimioterapia. |
| MX393780B (es) | 2017-01-17 | 2025-03-24 | Heparegenix Gmbh | Inhibidores de proteina cinasa para promover la regeneracion hepatica o reducir o prevenir la muerte de hepatocitos |
| US11395821B2 (en) | 2017-01-30 | 2022-07-26 | G1 Therapeutics, Inc. | Treatment of EGFR-driven cancer with fewer side effects |
| US11944627B2 (en) | 2017-03-24 | 2024-04-02 | Kura Oncology, Inc. | Methods for treating hematological malignancies and Ewing's sarcoma |
| WO2018226976A1 (en) | 2017-06-08 | 2018-12-13 | Kura Oncology, Inc. | Methods and compositions for inhibiting the interaction of menin with mll proteins |
| WO2019060365A1 (en) | 2017-09-20 | 2019-03-28 | Kura Oncology, Inc. | SUBSTITUTED MÉNINE-MLL INHIBITORS AND METHODS OF USE |
| CN110546150B (zh) * | 2017-10-19 | 2021-12-21 | 江苏豪森药业集团有限公司 | 含吡唑基的三并环类衍生物、其制备方法和应用 |
| CN111821434A (zh) * | 2019-04-17 | 2020-10-27 | 上海君实生物医药科技股份有限公司 | 抗pd-1抗体在制备治疗实体瘤的药物中的用途 |
| CN112996795B (zh) | 2018-09-18 | 2024-11-12 | 尼坎治疗公司 | 作为src同源-2磷酸酶抑制剂的稠合的三环衍生物 |
| CN112020357B (zh) * | 2019-04-02 | 2023-08-29 | 上海翰森生物医药科技有限公司 | 含吲唑基的三并环类衍生物的盐及其晶型 |
| US10988479B1 (en) | 2020-06-15 | 2021-04-27 | G1 Therapeutics, Inc. | Morphic forms of trilaciclib and methods of manufacture thereof |
| EP4322956A4 (en) * | 2021-04-16 | 2025-03-19 | Erasca, Inc. | Uses of heterocyclic inhibitors of erk1/2 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7151161B1 (en) * | 1998-01-13 | 2006-12-19 | Oscient Pharmaceuticals Corporation | Human genes of chromosome 11q13.3 |
| TW200536536A (en) * | 2004-02-25 | 2005-11-16 | Schering Corp | Pyrazolotriazines as kinase inhibitors |
| JP2006094733A (ja) * | 2004-09-28 | 2006-04-13 | As One Corp | 癌の検出方法 |
| WO2007103808A2 (en) * | 2006-03-02 | 2007-09-13 | The Ohio State University | Microrna expression profile associated with pancreatic cancer |
| US9655909B2 (en) * | 2012-01-12 | 2017-05-23 | Board Of Regents, The University Of Texas System | Personalized medicine for the prediction of therapy targeting the hedgehog pathway |
| JP6427197B2 (ja) * | 2013-10-03 | 2018-11-21 | クラ オンコロジー， インコーポレイテッド | Ｅｒｋの阻害剤および使用方法 |
-
2017
- 2017-06-19 CN CN201780051014.8A patent/CN109661228A/zh active Pending
- 2017-06-19 TW TW106120308A patent/TW201805000A/zh unknown
- 2017-06-19 EP EP17815990.1A patent/EP3471717A4/en not_active Withdrawn
- 2017-06-19 JP JP2018566377A patent/JP2019518063A/ja active Pending
- 2017-06-19 WO PCT/US2017/038084 patent/WO2017222958A1/en not_active Ceased
-
2018
- 2018-12-17 US US16/222,398 patent/US20190192517A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019518063A5 (enExample) | ||
| AU2009240021B2 (en) | Antiviral therapy | |
| US10407726B2 (en) | miRNA biomarkers for radiation biodosimetry | |
| JP2011529691A5 (enExample) | ||
| JP2012526554A5 (enExample) | ||
| CN103608683A (zh) | Hedgehog抑制剂治疗的生物标志物 | |
| JP2010528659A (ja) | 肝細胞癌のサブタイプを決定し、肝癌幹細胞を検出するための方法 | |
| US20140134158A1 (en) | Kras mutations and resistance to anti-egfr treatment | |
| JP2015531590A5 (enExample) | ||
| JP2011188853A5 (enExample) | ||
| CN107109494A (zh) | Il‑33介导型疾病的治疗方法和诊断方法 | |
| EP2191274A1 (en) | Method for predicting the response of a subject suffering from a viral infection of the liver to an antiviral therapy | |
| CN103402517A (zh) | 使用braf抑制剂的治疗方法 | |
| JP2015530868A5 (enExample) | ||
| JP2018527886A5 (enExample) | ||
| TW200902724A (en) | Gene expression in peripheral blood mononuclear cells from children with diabetes | |
| US20210348238A1 (en) | Tumor mutation burden alone or in combination with immune markers as biomarkers for predicting response to targeted therapy | |
| TW202014217A (zh) | 標靶gpr35以治療發炎性腸病症的組合物及方法 | |
| CA2907124A1 (en) | Assay for predictive biomarkers | |
| CA2660622A1 (en) | Rig-i mutations and uses thereof in diagnostic and therapeutic virus-dependent immune applications | |
| Ghaderzadeh et al. | Transcriptomic and biometric parameters analysis in rainbow trout (Oncorhynchus mykiss) challenged with viral hemorrhagic septicemia virus (VHSV) | |
| Kim et al. | Exploratory biomarker analysis from a phase II clinical trial of eribulin plus gemcitabine versus paclitaxel plus gemcitabine for HER2-negative metastatic breast cancer patients (KCSG BR13-11) | |
| JP6348699B2 (ja) | インターフェロン治療効果予測方法 | |
| US11952631B2 (en) | Diagnostics and therapy for human respiratory syncytial virus | |
| CN109937260A (zh) | 提供流感感染预后的组合物和方法 |